SCHEMBL1521763

SCHEMBL1521763

CN1C(=O)N(c2ccc(F)c(NC(=O)Nc3cc(C(C)(C)C)nn3C)c2)Cc2cnc(N)nc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABL1 P00519 2/20 0.43
TNK2 Q07912 2/20 0.43
MAP4K2 Q12851 2/20 0.43
LCK P06239 1/20 0.43
FES P07332 1/20 0.43
RET P07949 1/20 0.43
PDGFRB P09619 1/20 0.43
KIT P10721 1/20 0.43
FGFR1 P11362 1/20 0.43
SRC P12931 1/20 0.43
PDGFRA P16234 1/20 0.43
FLT1 P17948 1/20 0.43
FGFR3 P22607 1/20 0.43
EPHA3 P29320 1/20 0.43
KDR P35968 1/20 0.43
BMX P51813 1/20 0.43
EPHB4 P54760 1/20 0.43
TEK Q02763 1/20 0.43
KARS1 Q15046 1/20 0.43
NTRK3 Q16288 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1521814 0.91 MAPK14 (0.52) SRCMAPK14MAPK13MAPK12MAPK11
SCHEMBL1521820 0.91 FGFR4 (0.43) ABL1TNK2MAP4K2BMXMAPK14
SCHEMBL1521944 0.87 ABL1 (0.54) ABL1TNK2MAP4K2LCKFES
SCHEMBL1521545 0.86 MAPK14 (0.43) ABL1MAPK14MAPK13MAPK12MAPK11
SCHEMBL1521794 0.83 MAPK14 (0.44) ABL1KDRMAPK14MAPK13MAPK12
SCHEMBL1521734 0.82 MAPK14 (0.51) MAPK14MAPK13MAPK12MAPK11BRAF
SCHEMBL1521574 0.82 MAPK14 (0.41) ABL1TNK2MAP4K2MAPK14MAPK13
SCHEMBL1521977 0.78 TNK2 (0.49) ABL1TNK2MAP4K2KDRBMX
SCHEMBL1521807 0.78 MAPK14 (0.43) ABL1KDRMAPK14MAPK13MAPK12
SCHEMBL1521555 0.78 MAPK14 (0.53) MAPK14MAPK13MAPK12MAPK11BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US claimed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US claimed
EP-2063896-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES Deciphera Pharmaceuticals, LLC. (US) 2009-06-03 EP claimed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US claimed
WO-2008033999-A2 KINASE INHIBITORS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES DECIPHERA PHARMACEUTICALS, LLC (US) 2008-03-20 WO claimed
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases FLYNN DANIEL L 2011-05-19 US disclosed
US-7897762-B2 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2011-03-01 US disclosed
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases DECIPHERA PHARMACEUTICALS, LLC (US) 2009-04-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110118271-A1 Kinase Inhibitors Useful For The Treatment Of Proliferative Diseases BRAF, PRKDC, RAF1 ABL1 936/4885TNK2 119/4885MAP4K2 22/4885
US-20090099190-A1 Kinase inhibitors useful for the treatment of proliferative diseases BRAF, PRKDC, RAF1 ABL1 936/4885TNK2 119/4885MAP4K2 22/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.